Barclays PLC Acquires 56,110 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Barclays PLC increased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 18.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 352,494 shares of the company's stock after acquiring an additional 56,110 shares during the quarter. Barclays PLC owned approximately 0.11% of Amneal Pharmaceuticals worth $2,792,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth about $81,000. Straightline Group LLC acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter valued at $92,000. Cibc World Markets Corp bought a new stake in Amneal Pharmaceuticals in the fourth quarter worth about $118,000. Janney Montgomery Scott LLC bought a new stake in Amneal Pharmaceuticals during the fourth quarter worth approximately $121,000. Finally, Fox Run Management L.L.C. grew its holdings in shares of Amneal Pharmaceuticals by 69.0% in the 4th quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company's stock worth $162,000 after acquiring an additional 8,342 shares during the last quarter. Institutional investors own 31.82% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on AMRX. Barclays raised their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $10.80.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX traded up $0.23 on Friday, hitting $7.97. 4,829,305 shares of the company were exchanged, compared to its average volume of 1,424,376. The company's 50 day moving average price is $8.02 and its two-hundred day moving average price is $8.17. Amneal Pharmaceuticals, Inc. has a one year low of $5.81 and a one year high of $9.48. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of -11.72 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. The company had revenue of $695.42 million during the quarter, compared to analysts' expectations of $714.78 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. Research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the transaction, the director now directly owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. The trade was a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the transaction, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,160,000 shares of company stock valued at $43,113,200. 26.56% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.